Rein Therapeutics Inc. (NASDAQ:RNTX) Short Interest Up 25.5% in January

Rein Therapeutics Inc. (NASDAQ:RNTX) was the recipient of a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 441,027 shares, a growth of 25.5% from the January 15th total of 351,493 shares. Based on an average daily trading volume, of 140,201 shares, the days-to-cover ratio is presently 3.1 days. Currently, 1.8% of the company’s shares are short sold. Currently, 1.8% of the company’s shares are short sold. Based on an average daily trading volume, of 140,201 shares, the days-to-cover ratio is presently 3.1 days.

Rein Therapeutics Stock Performance

Shares of NASDAQ:RNTX traded up $0.03 during midday trading on Tuesday, hitting $1.15. 120,777 shares of the company’s stock traded hands, compared to its average volume of 108,131. The firm’s fifty day moving average price is $1.27 and its two-hundred day moving average price is $1.29. Rein Therapeutics has a twelve month low of $1.02 and a twelve month high of $2.96. The company has a market cap of $30.23 million, a PE ratio of -0.44 and a beta of 1.48.

Rein Therapeutics (NASDAQ:RNTX) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.03. As a group, equities research analysts anticipate that Rein Therapeutics will post -1.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Rein Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of RNTX. Gagnon Securities LLC grew its position in Rein Therapeutics by 5.0% in the fourth quarter. Gagnon Securities LLC now owns 240,220 shares of the company’s stock valued at $279,000 after acquiring an additional 11,528 shares in the last quarter. Gleason Group Inc. acquired a new stake in Rein Therapeutics during the 3rd quarter valued at $26,000. Blair William & Co. IL acquired a new stake in Rein Therapeutics during the 2nd quarter valued at $33,000. Meridian Wealth Advisors LLC purchased a new stake in Rein Therapeutics during the 2nd quarter worth $40,000. Finally, Exencial Wealth Advisors LLC acquired a new position in Rein Therapeutics in the 2nd quarter worth $43,000. 90.89% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Citigroup downgraded shares of Rein Therapeutics to a “hold” rating in a research note on Wednesday, January 21st. Loop Capital set a $6.00 price target on shares of Rein Therapeutics in a research report on Monday, November 3rd. Brookline Capital Acquisition lowered shares of Rein Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Rein Therapeutics in a research note on Thursday, January 22nd. Finally, Wall Street Zen lowered Rein Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, December 14th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Rein Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.